---
title: "Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Economic impact of diagnostic testing"
description: "Formulary evidence on Lorundrostat (MLS-101, MT-4129) in Hypertension, in combination with other antihypertensive drugs: Economic impact of diagnostic testing. Topics: Screening for primary aldosteronism with aldosterone and renin: Endocrine Society guideline; Cost and testing burden of broader primary aldosteronism screening: 2025 AHA/ACC guideline; Primary aldosteronism testing rates and treatment in 269 010 Veterans with apparent treatment-resistant hypertension; Underdiagnosis, downstream costs, and cost-effectiveness of broader screening: review; 8 further topics. 12 evidence topics quoted from 11 sources."
canonical: "https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description/economic-impact-of-diagnostic-testing"
published: "2026-11-18T10:43:00-05:00"
modified: "2026-11-18T10:43:00-05:00"
---

# Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Economic impact of diagnostic testing

<a id="heading-2.2.1.8.4"></a>

## 2.2.1.8.4 Economic Impact of Diagnostic Testing

<a id="topic-2.2.1.8.4-1"></a>

### Screening for primary aldosteronism with aldosterone and renin: Endocrine Society guideline

> “We suggest that all individuals with hypertension be screened for PA by measuring aldosterone and renin and determining the aldosterone to renin ratio, and that subsequent clinical care be guided by the results.”
> “The GDP used the GRADE Evidence to Decision (EtD) framework to consider contextual factors, such as stakeholder values and preferences, costs and required resources, cost-effectiveness, acceptability, feasibility, and the potential impact on health equity.”

Source: [Adler et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40658480/)

<a id="topic-2.2.1.8.4-2"></a>

### Cost and testing burden of broader primary aldosteronism screening: 2025 AHA/ACC guideline

> “Studies from Australia and Japan suggest that broader screening for primary aldosteronism in individuals with hypertension is cost-effective”
> “Nonetheless, the potential burden of additional testing outside of patients with resistant hypertension to confirm the diagnosis of primary aldosteronism and to determine optimal therapy may be taken into consideration prior to screening.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-2.2.1.8.4-3"></a>

### Primary aldosteronism testing rates and treatment in 269 010 Veterans with apparent treatment-resistant hypertension

> “Veterans with apparent treatment-resistant hypertension (n = 269 010) from 2000 to 2017”
> “4277 (1.6%) patients who were tested for primary aldosteronism were identified.”
> “Testing was associated with a 4-fold higher likelihood of initiating MRA therapy (HR, 4.10 [CI, 3.68 to 4.55]) and with better BP control over time.”
> “Testing for primary aldosteronism in patients with apparent treatment-resistant hypertension is cost-effective and may substantially improve long-term outcomes”

Source: [Cohen et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7965294/)

<a id="topic-2.2.1.8.4-4"></a>

### Underdiagnosis, downstream costs, and cost-effectiveness of broader screening: review

> “Fewer than 2% of eligible patients are screened for primary aldosteronism (PA) despite evidence that early detection and targeted therapy are associated with lower cardiovascular and kidney morbidity.”
> “The resulting underdiagnosis not only prolongs exposure to excess aldosterone but also increases healthcare utilization and costs through preventable hospitalizations, procedural interventions, and long-term management of aldosterone-mediated end-organ damage.”
> “In a modeling study focused on patients with apparent treatment resistant hypertension in the U.S., Gaziano et al. assessed the cost-effectiveness of multiple diagnostic strategies and an empiric MRA treatment approach. Screening with ARR followed by confirmatory testing, AVS, and surgical adrenalectomy, when appropriate, were cost-effective, with incremental cost-effectiveness ratios well within commonly accepted thresholds.”

Source: [Owei et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12885222/)

<a id="topic-2.2.1.8.4-5"></a>

### Cost-effectiveness of primary aldosteronism screening and subtype diagnosis in resistant hypertension: US decision model

> “At a U.S. WTP threshold of $150,000/QALY and without adjustments in HRQoL for patients with surgically untreated PA, CT/AVS strategy is the cost-effective choice with an ICER of $82,000/QALY”
> “ICERs for CT alone and AVS alone were $200,000/QALY and $492,000/QALY; the other strategies were more costly and less effective.”
> “Integrating differential patient-reported health-related quality of life adjustments for patients with PA, ICERs for screening patients with CT followed by AVS, CT alone, and AVS alone were $52,000/QALY, $114,000/QALY, and $269,000/QALY gained.”
> “CT scanning followed by AVS was a cost-effective strategy to screen for PA among patients with resistant hypertension.”

Source: [Lubitz et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4651757/)

| Test or procedure (CPT or DRG codes as printed) | Base-case cost |
| --- | --- |
| Screening aldosterone to renin ratio (CPT 82088, 84244, 84132) | “$93” |
| Confirmatory saline infusion testing (CPT 96365, 93666) | “$141” |
| Abdominal CT (CPT 74170) | “$329” |
| Adrenal venous sampling (CPT 75893, 36500) | “$2,645” |
| Adrenalectomy, surgery and anesthesia (CPT 60650, 00866) | “$3,054” |
| One year cost of spironolactone | “$158” |

Source: [Lubitz et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4651757/)

<a id="topic-2.2.1.8.4-6"></a>

### Medicare fee schedule costs of primary aldosteronism work-up and therapeutic drug monitoring-guided screening in resistant hypertension

> “Cost of therapeutic drug monitoring for three drugs=3×$25=$75”
> “Cost of screening for primary aldosteronism (PA)=$30 for plasma renin activity+$56 for serum aldosterone=$86”
> “Cost of adrenal vein sampling=$2328.73”
> “Cost of computed tomographic scan of adrenal glands=$588.53”
> “A retrospective analysis from a hypertension referral clinic showed that prevalence of PA in adherent patients with TRH by TDM was significantly higher than in nonadherent patients (28% vs 8%, P<.05). Furthermore, cost analysis showed that TDM‐guided PA screening was $590.69 less expensive per patient, with minimal impact on the diagnostic accuracy.”

Source: [Velasco et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4562815/)

<a id="topic-2.2.1.8.4-7"></a>

### Cost-effectiveness of primary aldosteronism screening in all adults with hypertension from age 40: Australian Markov model

> “A Markov model was used to estimate the cost-effectiveness of screening for primary aldosteronism in treatment and disease (cardiovascular disease and stroke) naive hypertensive patients.”
> “The results from this study demonstrated that screening all hypertensive patients for primary aldosteronism from age 40 is cost-effective.”

Source: [Woode et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37466447/)

<a id="topic-2.2.1.8.4-8"></a>

### Care-pathway cost of investigating secondary and apparent treatment-resistant hypertension in a specialist clinic: Ireland

> “Sixty-five patients originally recruited for a study of medication adherence in hypertension were included in the sample.”
> “The total care-pathway cost per patient, taking into account clinic visits, clinical reviews, investigations and MDT discussion, was estimated to be €3277, on average. For the patient subgroups, the average cost was €5644 for patients diagnosed with primary aldosteronism and €1446 for patients diagnosed with essential hypertension.”

Source: [Rabbitt et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38009268/)

<a id="topic-2.2.1.8.4-9"></a>

### Medicare coverage of ambulatory blood pressure monitoring

> “For dates of service on and after July 2, 2019, the Centers for Medicare & Medicaid Services (CMS) believes that the evidence is sufficient to determine that ABPM is reasonable and necessary for the diagnosis of hypertension in Medicare beneficiaries under the following circumstances”
> “For eligible patients, ABPM is covered once per year.”
> “Coverage of other indications for ABPM not indicated above are at the discretion of the Medicare Administrative Contractors.”

Source: [CMS National Coverage Determination 20.19, ambulatory blood pressure monitoring (2019)](https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?ncdid=254)

<a id="topic-2.2.1.8.4-10"></a>

### Cost-effectiveness of clinic, home, and ambulatory blood pressure measurement for diagnosis: US model

> “We compared quality-adjusted life-years and lifetime costs ($US 2017 from the US healthcare perspective) associated with clinic BP measurement, home BP monitoring, and ABPM under 2 scenarios: positive and negative initial screen.”
> “In the screen-positive scenario, ABPM was the dominant strategy among all age and sex groups. Compared with clinic BP measurement, ABPM was associated with cost-savings ranging from $77 (women 80 years of age) to $5013 (women 21 years of age).”
> “ABPM is recommended as the diagnostic strategy of choice for most adults in primary care settings regardless of initial screening results.”

Source: [Beyhaghi and Viera (2019)](https://pubmed.ncbi.nlm.nih.gov/30571548/)

<a id="topic-2.2.1.8.4-11"></a>

### Practicality and availability of home and ambulatory blood pressure monitoring: 2025 AHA/ACC guideline

> “Further, HBPM is often a more practical approach in clinical practice than ABPM and may be more reproducible and accessible, supporting its use for longitudinal management and titration of BP-lowering medication.”
> “Additional studies comparing home and ambulatory BP measurements in estimating CVD risk are greatly needed to reduce treatment disparities due to lack of availability of ABPM to all populations.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-2.2.1.8.4-12"></a>

### Costs and cost-effectiveness of self-measured blood pressure monitoring: Community Guide systematic review of 22 studies

> “The literature search from database inception to March 2015 identified 22 studies for inclusion with three types of interventions: SMBP used alone, SMBP with additional support, and SMBP within team-based care (TBC).”
> “Median costs of intervention were $60 and $174 per person for SMBP alone and SMBP with additional support, respectively, and $732 per person per year for SMBP within TBC.”
> “SMBP monitoring interventions with additional support or within TBC are cost effective. Cost effectiveness of SMBP used alone could not be determined.”

Source: [Jacob et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5657494/)

## Related pages
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Terms and abbreviations](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations.md)
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Product information and disease description](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Clinical evidence](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Economic information and modeling report](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: References](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references.md)
